Interleukin said in July that it would liquidate its assets after laying off 63 percent of its workforce and suspending sales of its controversial genetic test.
Investment banks Canaccord Genuity and Raymond James also raised their price targets on the company.
Population Genetics was formed to commercialize the IP portfolio of Sydney Brenner focused on high sensitivity and high specificity NGS detection.
The purchase provides Thermo Fisher with access to the $40 billion pharmaceutical contract development and manufacturing market.
Headed by Nuclea's former Founder and CEO Patrick Muraca, NanoMolecular aims to commercialize cancer diagnostics including Nuclea's Her2/neu assay.
The clinical genetics and genomics testing firm said the funding will help as it seeks to consolidate its presence in international markets.
The acquisition of GeneWorks' oligo business widens IDT's reach in the Asia-Pacific region, the company said.
CareDx's CareDx Pty subsidiary said it will pay up to $735,000 to Conexio as a percentage of revenues from products acquired in the deal.
In addition to variant detection technology, Omicia also gets technologies like data compression, which will aid diagnostics development and data storage.
The deal, completed this month with cash reserves for an undisclosed price, adds scalability and multi-omics analysis to Qiagen's bioinformatics portfolio.
Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.
The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.
CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.
In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.